Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.

Muntz, Howard G; Malpass, Thomas W; McGonigle, Kathryn F; Robertson, Mandy D; Weiden, Paul L

Muntz, Howard G; Malpass, Thomas W; McGonigle, Kathryn F; Robertson, Mandy D; Weiden, Paul L.

Affiliation

Muntz HG; Women's Cancer Care of Seattle, Northwest Hospital and Medical Center, Seattle, Washington 98133, USA. howard.muntz@nwhsea.org

Cancer ; 113(3): 490-6, 2008 Aug 01.

Article in En | MEDLINE | ID: mdl-18521923

Subject(s)

Carcinoma/drug therapy; Ovarian Neoplasms/drug therapy; Peritoneal Neoplasms/drug therapy; Topotecan/administration & dosage; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Carcinoma/mortality; Female; Humans; Infusions, Parenteral; Middle Aged; Models, Biological; Ovarian Neoplasms/mortality; Salvage Therapy; Survival Analysis; Topotecan/adverse effects; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Carcinoma / Topotecan Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Cancer Year: 2008 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google